Cannabinoids

494 J. Fernández-Ruiz and S. González

Table 2.

(continued

)

Compound

Disease

Therapeutic application

Inhibitors of endocannabinoid inactivationAM404

Huntington’s disease

Antihyperkinetic activity and recovery from neurochemic

al deficits in 3NP-lesioned rats (involvement of VR1 receptor

s)

(Lastres-Becker et al. 2002a, 2003a)

Parkinson’s disease

Unable to reduce

l-dopa-induced dyskinesia in the reserpine rat model (Segovia et al. 2003)

VDM11

Huntington’s disease

Not effective in 3NP-lesioned rats (Lastres-Becker et al.

2003a)

UCM707

Huntington’s disease

Certain antihyperkinetic ac

tivity in 3NP-lesioned rats (de Lago et al. 2004c)

AM374

Huntington’s disease

Not effective in 3NP-lesioned rats (Lastres-Becker et al.

2003a)

Receptor antagonistsSR141716 (CB1)

Huntington’s disease

Increased striatal damage in the

malonate rat model (Lastres-Becker et al. 2003c)

Unable to reverse antihyperkinetic effects of AM404 in 3NP-lesioned rats (Lastres-B

ecker et al. 2003a)

Unable to reduce late akinesia in 3NP-lesioned rats (Lastres-Becker et al. 2002b)

Parkinson’s disease

Effective to reduce

l-dopa-induced dyskinesia in MPTP-treated marmosets and the reserpine rat

model

(Brotchie 1998, 2000; Segovia et al. 2003)Unable to reverse bradykinesia and rigidity in MPTP-treated primates (Meschler

et al. 2001)

Able to restore locomotion in the reserpine model of PD (Di Marzo et al. 2000a)

SR144528 (CB2)

Huntington’s disease

Able to reverse neuropr

otective effect of HU308 in the malonate rat model (Aroyo et al. 2005)

Capsazepine (VR1) Huntington’s disease

Able to reverse antihyperkinetic effec

ts of AM404 in 3NP-lesioned rats (Lastres-Becker et al. 2003a)

3NP, 3-nitropropionic acid; HD, Huntington’s disease; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrah

ydropyridine; PD, Parkinson’s disease.